Hyperliquid Labs to unstake and sell $320M in HYPE via OTC deal
Ecosystem ·
Hyperliquid Labs is unstaking $320 million worth of HYPE tokens today as part of its monthly team unlock and selling the tokens over-the-counter to an investor.
Hyperliquid Labs announced it will unstake HYPE tokens valued at $320 million today, part of a recurring monthly unlock schedule tied to the team's allocation. Rather than releasing the tokens onto the open market, the project said the unstaked HYPE will be sold directly to an investor through an over-the-counter transaction.
The mechanism separates this unlock from a typical exchange-based sale. An OTC deal moves the tokens in a single negotiated transaction with a buyer rather than through order books, which can reduce the immediate price impact that a large open-market sale might otherwise cause. Because the unlock is described as monthly, this event follows a recurring schedule for team-allocated tokens rather than a one-time distribution.
Four separate sources describe the same transaction, consistently citing the $320 million figure, the OTC structure, and the characterization of the buyer as an institutional investor. The corroborating accounts align on the core facts: Hyperliquid Labs is the seller, the unstaking is tied to the monthly team unlock, and the sale is being conducted off exchange rather than on the open market.
What remains unspecified across the available material is the identity of the investor or institution purchasing the tokens, the price or valuation terms of the OTC deal, and whether this transaction represents a new arrangement or a continuation of prior monthly unlock sales conducted the same way. It is also not clear from the material whether additional unlocks of similar size are scheduled in coming months or what portion of the total team allocation this $320 million represents.
Market participants will likely watch for any on-chain confirmation of the unstaking event, disclosure of the buyer's identity, and whether subsequent monthly unlocks follow the same OTC pattern rather than being distributed through exchanges.